Avizakimab
Based on 1 Customer Validation
Avizakimab (BOS161721) is a humanized IgG1 monoclonal antibody that targets interleukin-21.
For research use only. We do not sell to patients.
- Purity : 99.69%
- CAS No.: 2229685-51-0
- Molecular Weight:145.2 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IL-21
In Vitro
Avizakimab (BOS161721) prevents IL-21 binding to the IL-21 receptor (IL-21R) and inhibits bioactivity[1].
Avizakimab inhibits the downstream signaling, plasma cell differentiation, and natural killer cell activation induced by IL-21 and suppressed antibody responses to keyhole limpet hemocyanin (KLH) antigen[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2229685-51-0
-
Appearance Liquid
-
Molecular Weight 145.2 kDa
-
Color Colorless to light yellow
-
SMILES
[Avizakimab]
-
Synonyms
BOS161721
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)